GSK chief confident China R&D investment will be a success; Will Eli Lilly's Alzheimer's gamble pay off?;

@FierceBiotech: Social media jump-starts stalled patient recruitment efforts. Piece | Follow @FierceBiotech

@JohnCFierce: GSK's Witty confident the co. will be rewarded for big R&D investment in China. Translation: They won't get stiffed. Article | Follow @JohnCFierce

@RyanMFierce: NCI's cancer informatics group says goodbye to chief after program stalls. News via @bioitworld. Story | Follow @RyanMFierce

@FierceMedDev: Youngstown News, New motion-sensor technology eases debilitating pain of Boardman man. News via @vindicator. Story | Follow @FierceMedDev

> In a Bloomberg interview, GlaxoSmithKline's ($GSK) Andrew Witty (photo) said he was confident the pharma giant's big R&D investment in China would pay off, noting that in "every dialogue I've had with the Chinese government, there's a really strong awareness and interest in continued access to innovation, and a strong understanding about reward for innovation." Story

> The Houston Chronicle covers the story of a Texas A&M experiment, creating goats that can produce a malaria vaccine in their milk. Scientists are working with GTC Biotherapeutics on a new approach to protecting children in developing countries. News

> The U.K.'s Phosphate Therapeutics has raised $13.8 million from Inventages Venture Capital. The biotech plans to use the money to develop a new drug for hyperphosphatemia. Report

Pharma News

@FiercePharma: China's health minister scolds hospitals for profiting off high-priced drugs--Reuters. News | Follow @FiercePharma

> Greece making drugmakers cover overspending on meds. Item

> Merck's new cholesterol combo faces delay. News

> How worrisome is the statin-diabetes link? Report

> Chinese official chides hospitals for high drug prices. Story

> EC drops antitrust probe aimed at GSK. Article

Medical Device News

> Mouth sensor, iPhone boost quadriplegics' mobility. Item

> Structural heart disease devicemaker lands $250K in seed money. News

> Australia's TGA slammed for device safety oversight. Article

> Families sue Synthes, former execs over deaths in bone cement case. Story

IT News

> Aptiv marries IT and CRO services to tackle adaptive trials market. Story

> NIH backs effort to integrate clinical trials data into EHRs. Article

> Social media jump-starts stalled patient recruitment efforts. Item

And Finally… MedCity News takes a crack at the big clinical showdown this year between Eli Lilly ($LLY) and a partnership led by J&J ($JNJ). Both are in Phase III with rival Alzheimer's drugs, and the risks they are running are extremely high. And the stakes are particularly high for Lilly, which has seen plunging profits in recent months. Report

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.